Taiwan–Korea Biotech Deals: Formosa–Samil Path

Key Takeaways

• Formosa (6838.TW) licensed APP13007 to Samil (000520.KS) for exclusive South Korea commercialization on 12 January 2026, with upfront, sales milestones, and royalties.
• On 11 June 2026 the same partners added an exclusive Vietnam commercialization license for APP13007, extending a 2024 CMO relationship.
• FDA review materials for NDA 218158 support clobetasol propionate ophthalmic suspension 0.05% for post-operative ocular inflammation and pain at one drop twice daily for two weeks.
• BIO Asia–Taiwan 2026 reported almost 150,000 visits and more than 10,000 partnering meetings, reinforcing Taiwan as an Asia deal hub.

Taiwan–Korea partnership at a glance

Field	Detail
Taiwan licensor	Formosa Pharmaceuticals (6838.TW), APNT nanoparticle platform
Korea partner	Samil Pharmaceuticals (000520.KS), ophthalmology-focused pharma founded 1947
Asset	APP13007 — clobetasol propionate ophthalmic suspension 0.05%
Korea license	Exclusive commercialization rights, 12 January 2026 (PR Newswire)
Vietnam extension	Exclusive commercialization rights, 11 June 2026 (PR Newswire)
US regulatory base	NDA 218158; dosing one drop BID for 14 days in FDA clinical review
Regional event signal	BIO Asia–Taiwan 2026: ~60 countries, >10,000 partnering meetings

Why replace a thin Korea–Taiwan tip with Formosa–Samil?

Conference panels about “why Korea, why now” rarely publish allowlisted deal terms. Formosa and Samil did. The January 2026 Korea license and June 2026 Vietnam follow-on give APAC readers a verified bilateral case study: Taiwan innovation out-licensed to a Korean commercial specialist that already runs ophthalmology networks and a Vietnam manufacturing footprint.

That is the partnership frontier that matters for BD teams—signed rights, dosing claims grounded in FDA review, and a second geography added within six months—not unverified session quotes from secondary trade sites.

What did the January 2026 Korea license actually convey?

In its 12 January 2026 PR Newswire release, Formosa said Samil received exclusive rights to commercialize APP13007 in South Korea. The agreement includes an upfront payment, sales milestones, and royalties for the term. Dollar totals were not disclosed in that wire.

Formosa framed APP13007 as a superpotent corticosteroid nanosuspension from its APNT platform, with a twice-daily, 14-day regimen. It cited a US survey of 100 ophthalmic surgeons highlighting ~80% pain-free four days post-surgery and adverse-event incidence under 2% as prescribing drivers. It also estimated nearly 800,000 cataract surgeries annually in South Korea among more than 600,000 patients receiving major ocular procedures each year.

CEO Erick Co said Formosa was expanding its relationship with Samil to serve Korean ocular surgery patients and described APP13007 as poised to be the first ophthalmic steroid introduced since 2008. Samil Chairman Seungbum Huh tied the license to a 2024 CMO agreement and pointed to global trials plus US FDA approval as the efficacy and safety base for Korea commercialization.

How did the June 2026 Vietnam deal extend the corridor?

The 11 June 2026 PR Newswire release shows the same partners adding exclusive Vietnam commercialization rights for APP13007, again with upfront payment, regulatory milestones, and royalties.

Samil CEO Seung-Bum Huh explicitly linked the Vietnam license to the January 2026 Korea agreement and said the company would advance regulatory approval and launch preparations in both markets. Formosa’s wire said cataract surgeries in Vietnam are reaching 300,000 annually with about 5% annual demand growth, and cited 2024 IQVIA data putting Vietnam’s ophthalmic corticosteroid market at US$4.26 million in annual sales.

For APAC strategy, the sequence matters: Taiwan IP → Korean exclusive rights → Korean partner’s ASEAN market (Vietnam) with WHO GMP manufacturing already disclosed for Samil’s Ho Chi Minh City site. That is a practical Korea–Taiwan–ASEAN corridor, not a one-country licensing island.

What does the FDA record say about APP13007?

Company wires claim US FDA approval; the public FDA clinical review for NDA 218158 (clobetasol propionate ophthalmic suspension 0.05%) documents the evidence package Formosa submitted. The reviewer’s product introduction identifies APP13007 as a milled-particle aqueous nanosuspension. The proposed regimen is one drop twice daily for two weeks for post-operative pain and inflammation after ocular surgery.

The clinical review recommends approval with revised labeling and says primary effectiveness rests on two randomized, double-masked, placebo-controlled Phase 3 trials (CPN-301 and CPN-302), with a Phase 2 dose-ranging study as support. PDUFA goal date in the review header is 4 March 2024. Readers should treat Korea and Vietnam launches as still subject to local regulatory clearance; the FDA file supports the US product, not automatic APAC registration.

How does BIO Asia–Taiwan 2026 frame the regional opportunity?

On 21 July 2026, Taiwan Bio Industry Organization said BIO Asia–Taiwan 2026 closed with record engagement: 22 national delegations, 900 exhibitors, 2,300 booths, attendees from nearly 60 countries, and almost 150,000 visits, according to Taiwan BIO’s PR Newswire wrap-up.

Chairman Johnsee Lee said Taiwan’s biotech sector now generates over NT$800 billion (US$25 billion) in annual revenue and described a shift from “In Taiwan” and “From Taiwan” to “With Taiwan” as a preferred global partner. The same release said the conference drew more than 3,500 biotech professionals and that BIO Partnering surpassed 10,000 scheduled meetings.

Those numbers do not invent a Korea–Taiwan free-trade corridor by themselves. They do show why Taipei is a high-density venue for the kind of license Formosa and Samil already executed: CDMO, ophthalmology, and cross-border commercialization meetings at scale.

What should BD teams watch next?

Three watch items follow from the primaries. First, Korea MFDS filing and launch timing for APP13007 under Samil’s exclusive rights—terms beyond “upfront + milestones + royalties” were not disclosed. Second, Vietnam regulatory milestones under the June 2026 license. Third, whether Formosa’s broader “Double A” ADC plus APNT strategy yields more Korea-facing licenses after the APP13007 template.

Unproven in the cited wires: total deal NPV, Korea peak sales, and whether APP13007 will be the first ophthalmic steroid launched in Korea since 2008 as Formosa’s CEO stated. Those remain company claims until local filings and launch data appear.

Related NovaPharma coverage includes Insilico Medicine’s alliance with Bora Pharmaceuticals, drug-discovery technology market sizing to 2035, and TGA Australia drug-approval coverage.

Frequently Asked Questions

Primary Sources

1. Formosa–Samil APP13007 South Korea exclusive license (PR Newswire, 12 Jan 2026)
2. Formosa–Samil APP13007 Vietnam exclusive license (PR Newswire, 11 Jun 2026)
3. FDA clinical review, NDA 218158 clobetasol propionate ophthalmic suspension 0.05%
4. Taiwan BIO: BIO Asia–Taiwan 2026 wrap-up (PR Newswire, 21 Jul 2026)